Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩1,000,000.00
Day range
₩1,005,000.00 - ₩1,044,000.00
Year range
₩721,000.00 - ₩1,113,000.00
Market cap
72.03T KRW
Avg Volume
71.47K
P/E ratio
68.43
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
(KRW) | Sep 2024info | Y/Y change |
---|---|---|
Revenue | 1.19T | 14.81% |
Operating expense | 202.29B | 11.50% |
Net income | 264.47B | 10.03% |
Net profit margin | 22.28 | -4.17% |
Earnings per share | 3.72K | 10.07% |
EBITDA | 495.40B | 8.39% |
Effective tax rate | 9.12% | — |
Balance Sheet
Total assets
Total liabilities
(KRW) | Sep 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 988.11B | -45.63% |
Total assets | 16.03T | 0.87% |
Total liabilities | 5.43T | -14.30% |
Total equity | 10.59T | — |
Shares outstanding | 71.17M | — |
Price to book | 6.72 | — |
Return on assets | 5.23% | — |
Return on capital | 7.18% | — |
Cash Flow
Net change in cash
(KRW) | Sep 2024info | Y/Y change |
---|---|---|
Net income | 264.47B | 10.03% |
Cash from operations | 740.39B | 154.07% |
Cash from investing | -437.12B | -17.41% |
Cash from financing | -713.37B | -297.72% |
Net change in cash | -433.28B | -69.49% |
Free cash flow | -12.12B | -237.42% |
About
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Founded
2011
Website
Employees
4,744